X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-finds-new-manufacturing-lapses-eli-lilly-plant-2024-01-19/
https://www.reuters.com/legal/litigation/teva-drops-migraine-drug-patent-case-against-eli-lilly-2023-11-24/#:~:text=The%20filing%20follows%20a%20judge\\\'s,dismissed%20on%20Wednesday%20in%202021
https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lillys-migraine-drug-fails-meet-main-goal-post-approval-study-2023-06-16/
https://www.prnewswire.com/news-releases/first-of-its-kind-head-to-head-clinical-trial-reaffirms-the-efficacy-of-emgality-in-episodic-migraine-prevention-301852663.html
https://www.prnewswire.com/news-releases/affamed-therapeutics-to-commercialize-galcanezumab-for-migraine-prevention-in-mainland-china-301720180.html
https://www.fiercepharma.com/marketing/eli-lilly-hit-migraine-drug-launch-slowdown-and-reyvow-no-show-rivals-biohaven-abbvie
https://www.clinicaltrialsarena.com/news/lilly-enrolment-emgality-migraine/
https://www.fiercebiotech.com/biotech/migraine-market-better-make-way-for-abbvie-as-oral-preventative-treatment-atogepant-poised
https://www.biospace.com/article/releases/emgality-and-174-galcanezumab-now-approved-for-use-in-canada-for-the-treatment-of-episodic-cluster-headache/
https://www.fiercepharma.com/marketing/sanofi-foots-bill-collaboration-parkinson-s-foundation-for-genetic-testing-disease
http://www.pharmafile.com/news/564049/nice-recommends-lillys-emgality-chronic-and-episodic-migraine
https://www.biospectrumasia.com/news/50/17035/eli-lilly-collaborates-with-daiichi-sankyo-for-commercialisation-of-migraine-drug-in-japan.html
https://www.daiichisankyo.com/media/press_release/detail/index_4086.html#:~:text=Sankyo%20Company%2C%20Limited-,Eli%20Lilly%20and%20Daiichi%20Sankyo%20Enter%20Commercialization%20Collaboration,for%20Anti%2DCGRP%20Antibody%20Galcanezumab&text=Under%20the%20terms%20of%20the,and%20sales%20after%20marketing%20approval.
https://www.thetimes.co.uk/article/migraine-drug-galcanezumab-offers-hope-for-millions-of-sufferers-q53m23sdd
https://www.fiercepharma.com/pharma/lilly-touts-emgality-s-ability-to-reduce-migraine-patients-overall-pain-a-holistic-approach
https://www.prnewswire.com/news-releases/emgality-demonstrates-reduction-in-frequency-duration-and-pain-severity-in-patients-with-episodic-and-chronic-migraine-301078159.html
https://www.fiercepharma.com/pharma/lilly-s-pressing-ahead-its-emgality-rollout-and-now-it-wants-to-learn-more-about-cgrp-drug-s
https://endpts.com/lillys-emgality-clears-pivotal-study-in-migraine-patients-who-have-not-benefited-from-prior-preventative-therapy/
https://www.prnewswire.com:443/news-releases/ahs-2019-post-hoc-analyses-of-phase-3-pivotal-studies-of-emgality-galcanezumab-gnlm-show-improvements-in-daily-functioning-and-reductions-in-disability-in-patients-with-chronic-and-episodic-migraine-300883560.html
https://www.fiercepharma.com/marketing/biohaven-touts-oral-cgrp-data-moves-closer-to-regulatory-finish-line-and-maybe-m-a
https://www.fiercepharma.com/pharma/amid-important-launches-lilly-s-bio-medicines-head-shaw-steps-aside
https://in.reuters.com/article/us-health-headaches-cluster-migraine/studies-explore-treatments-to-prevent-cluster-headaches-quell-migraines-idINKCN1U52PB
https://www.fiercepharma.com/marketing/eli-lilly-turns-to-patients-to-market-new-emgality-indication-cluster-headaches
https://www.fiercepharma.com/pharma/lilly-scores-cluster-headache-nod-for-emgality-how-will-it-affect-cgrp-race
https://www.reuters.com/article/us-lilly-migraine-share/lillys-new-migraine-drug-pulls-ahead-of-amgen-in-fierce-battle-for-new-prescriptions-idUSKCN1SG28C
http://www.pharmafile.com/news/521966/eli-lillys-emgality-shows-positive-phase-3-results-treatment-migraine
https://www.biospace.com/article/releases/lilly-receives-fda-priority-review-designation-for-emgality-galcanezumab-gnlm-injection-for-the-preventive-treatment-of-episodic-cluster-headache-in-adults/
https://www.fiercepharma.com/marketing/can-botox-hang-cgrp-migraine-allergan-says-yes-but-analysts-are-skeptical
https://endpts.com/eli-lilly-has-anted-up-for-its-next-big-bet-on-a-next-gen-pain-drug-buying-hydra-assets/
https://www.biospace.com/article/top-9-really-cool-life-science-discoveries-of-the-year/
https://www.fiercepharma.com/pharma/eli-lilly-weighs-200m-plus-sale-declining-china-drug-portfolio-report
https://www.fiercebiotech.com/biotech/lilly-files-for-fda-approval-migraine-drug-lasmiditan
https://www.prnewswire.com/news-releases/lilly-submits-new-drug-application-to-the-fda-for-lasmiditan-for-acute-treatment-of-migraine-receives-breakthrough-therapy-designation-for-emgality-galcanezumab-gnlm-for-prevention-of-episodic-cluster-headache-300750141.html
https://www.biopharmadive.com/news/amgen-lilly-migraine-drugs-make-it-onto-express-scripts-preferred-list/539930/
https://www.fiercepharma.com/manufacturing/teva-has-buyer-for-plant-israel-could-save-200-jobs-report
https://www.fiercepharma.com/pharma/was-last-week-s-teva-sell-off-warranted-depends-who-you-ask
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761063
https://www.xconomy.com/indiana/2018/09/28/eli-lilly-migraine-drug-approved-the-third-in-new-class-of-medicines/
https://www.marketwatch.com/story/three-new-drugs-will-compete-fiercely-to-revolutionize-migraine-treatment-with-identical-6900-price-tags-2018-09-27
https://www.businessinsider.in/A-new-medication-thats-changing-the-way-we-treat-a-condition-that-affects-38-million-Americans-just-got-approved/articleshow/65987883.cms
https://www.marketwatch.com/story/eli-lilly-says-fda-has-approved-new-migraine-drug-emgality-2018-09-27
http://www.pharmatimes.com/news/chmp_puts_13_therapies_forward_for_eu_approval_1253165
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-september-2018
https://www.ema.europa.eu/documents/press-release/new-medicine-prevention-migraine_en.pdf
https://www.prnewswire.com/news-releases/lilly-receives-positive-chmp-opinion-for-emgality-galcanezumab-for-the-prophylaxis-of-migraine-in-adults-300716793.html
Market Place
Share 
